Knockdown of POLA2 increases gemcitabine resistance in lung cancer cells

详细信息    查看全文

• 作者：Vivien Koh ; Hsueh Yin Kwan ; Woei Loon Tan ; Tzia Liang Mah ; Wei Peng Yong
• 关键词：POLA2 ; Gemcitabine ; Non ; small cell lung cancer ; Drug response ; Single nucleotide polymorphism
• 刊名：BMC Genomics
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：17
• 期：13-supp
• 全文大小：1157KB
• 刊物主题：Life Sciences, general; Microarrays; Proteomics; Animal Genetics and Genomics; Microbial Genetics and Genomics; Plant Genetics & Genomics;
• 出版者：BioMed Central
• ISSN：1471-2164
• 卷排序：17

文摘

BackgroundGemcitabine is used as a standard drug treatment for non-small cell lung cancer (NSCLC), but treatment responses vary among patients. Our previous studies demonstrated that POLA2 + 1747 GG/GA single nucleotide polymorphism (SNP) improves differential survivability and mortality in NSCLC patients. Here, we determined the association between POLA2 and gemcitabine treatment in human lung cancer cells.